Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
Status:
Completed
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the effect of second-line irinotecan and capecitabine
versus irinotecan alone for gemcitabine and cisplatin refractory advanced biliary tract
cancer patients.